Evaxion, a clinical-stage biotechnology company specializing in AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with its AI platform, EDEN. The company’s CEO expressed excitement about the ability of their AI platforms to quickly generate novel vaccine targets and accelerate vaccine development. This innovation not only reduces costs but also minimizes risks, particularly in areas with high unmet medical needs lacking existing vaccines. Evaxion believes that these findings will make a significant difference in the fight against bacterial diseases.
EDEN, the proprietary AI platform developed by Evaxion, has been validated as capable of selecting immunologically relevant vaccine targets in a completely automated and unbiased manner. Through proteome-wide AI predictions, EDEN not only identifies protective proteins but also predicts the level of protection each offers. This important validation makes Evaxion the first organization to design bacterial vaccine antigens solely through computational methods, surpassing traditional reverse vaccinology approaches and marking a paradigm shift in vaccine discovery.
At the upcoming Vaccines Europe conference, Evaxion will present compelling data affirming the capabilities of EDEN through multiple bacterial pathogens and preclinical infection models. The antigens predicted by EDEN to offer the highest level of protection consistently perform well in these infection models, confirming their potential as vaccine components. This correlation between AI prediction and in vivo protection has been established for multiple bacterial pathogens that currently lack human vaccines.
EDEN is an AI-driven platform that rapidly identifies antigens capable of triggering a robust and highly protective immune response against bacterial infectious diseases. The platform represents a novel approach to vaccine development, aiming to combat the global issue of antibiotic resistance. Evaxion’s mission is to transform patients’ lives by providing innovative and targeted treatment options for unmet clinical needs.
Evaxion, a clinical-stage biotech company, is developing world-leading AI platforms to decode the human immune system and develop novel immunotherapies for cancer, bacterial, and viral diseases. The company is committed to providing transformative treatments by harnessing the power of AI. Evaxion’s groundbreaking immunotherapies aim to address the growing challenges posed by various diseases.
Disclaimer: This article contains forward-looking statements within the meaning of applicable securities laws. Actual results may differ materially from those indicated due to various factors, including financial conditions, product development success, market acceptance, partnerships, government regulations, intellectual property rights, and other uncertainties. The company does not assume any obligation to update these forward-looking statements except as required by law.
